OBJECTIVE:Juvenile fibromyalgia syndrome (FMS) is a chronic musculoskeletal pain disorder in children and adolescents for which there are no evidence-based treatments. The objective of this multisite, single-blind, randomized clinical trial was to test whether cognitive-behavioral therapy (CBT) was superior to fibromyalgia (FM) education in reducing functional disability, pain, and symptoms of depression in juvenile FMS. METHODS:Participants were 114 adolescents (ages 11-18 years) with juvenile FMS. After receiving stable medications for 8 weeks, patients were randomized to either CBT or FM education and received 8 weekly individual sessions with a therapist and 2 booster sessions. Assessments were conducted at baseline, immediately following the 8-week treatment phase, and at 6-month followup. RESULTS: The majority of patients (87.7%) completed the trial per protocol. Intent-to-treat analyses showed that patients in both groups had significant reductions in functional disability, pain, and symptoms of depression at the end of the study, and CBT was significantly superior to FM education in reducing the primary outcome of functional disability (mean baseline to end-of-treatment difference between groups 5.39 [95% confidence interval 1.57, 9.22]). Reduction in symptoms of depression was clinically significant for both groups, with mean scores in the range of normal/nondepressed by the end of the study. Reduction in pain was not clinically significant for either group (<30% decrease in pain). There were no study-related adverse events. CONCLUSION: In this controlled trial, CBT was found to be a safe and effective treatment for reducing functional disability and symptoms of depression in adolescents with juvenile FMS.
RCT Entities:
OBJECTIVE:Juvenile fibromyalgia syndrome (FMS) is a chronic musculoskeletal pain disorder in children and adolescents for which there are no evidence-based treatments. The objective of this multisite, single-blind, randomized clinical trial was to test whether cognitive-behavioral therapy (CBT) was superior to fibromyalgia (FM) education in reducing functional disability, pain, and symptoms of depression in juvenile FMS. METHODS:Participants were 114 adolescents (ages 11-18 years) with juvenile FMS. After receiving stable medications for 8 weeks, patients were randomized to either CBT or FM education and received 8 weekly individual sessions with a therapist and 2 booster sessions. Assessments were conducted at baseline, immediately following the 8-week treatment phase, and at 6-month followup. RESULTS: The majority of patients (87.7%) completed the trial per protocol. Intent-to-treat analyses showed that patients in both groups had significant reductions in functional disability, pain, and symptoms of depression at the end of the study, and CBT was significantly superior to FM education in reducing the primary outcome of functional disability (mean baseline to end-of-treatment difference between groups 5.39 [95% confidence interval 1.57, 9.22]). Reduction in symptoms of depression was clinically significant for both groups, with mean scores in the range of normal/nondepressed by the end of the study. Reduction in pain was not clinically significant for either group (<30% decrease in pain). There were no study-related adverse events. CONCLUSION: In this controlled trial, CBT was found to be a safe and effective treatment for reducing functional disability and symptoms of depression in adolescents with juvenile FMS.
Authors: J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan Journal: J Am Acad Child Adolesc Psychiatry Date: 1997-07 Impact factor: 8.829
Authors: Susmita Kashikar-Zuck; Stacy R Flowers; Robyn Lewis Claar; Jessica W Guite; Deirdre E Logan; Anne M Lynch-Jordan; Tonya M Palermo; Anna C Wilson Journal: Pain Date: 2011-03-31 Impact factor: 6.961
Authors: Pamela J Degotardi; Emily S Klass; Batya S Rosenberg; Diana G Fox; Kim A Gallelli; Beth S Gottlieb Journal: J Pediatr Psychol Date: 2005-08-24
Authors: S A Epstein; G Kay; D Clauw; R Heaton; D Klein; L Krupp; J Kuck; V Leslie; D Masur; M Wagner; R Waid; S Zisook Journal: Psychosomatics Date: 1999 Jan-Feb Impact factor: 2.386
Authors: Patrick J McGrath; Gary A Walco; Dennis C Turk; Robert H Dworkin; Mark T Brown; Karina Davidson; Christopher Eccleston; G Allen Finley; Kenneth Goldschneider; Lynne Haverkos; Sharon H Hertz; Gustaf Ljungman; Tonya Palermo; Bob A Rappaport; Thomas Rhodes; Neil Schechter; Jane Scott; Navil Sethna; Ola K Svensson; Jennifer Stinson; Carl L von Baeyer; Lynn Walker; Steven Weisman; Richard E White; Anne Zajicek; Lonnie Zeltzer Journal: J Pain Date: 2008-06-17 Impact factor: 5.820
Authors: Ather Ali; Theresa R Weiss; Anne Dutton; Douglas McKee; Kim D Jones; Susmita Kashikar-Zuck; Wendy K Silverman; Eugene D Shapiro Journal: J Pediatr Date: 2017-01-12 Impact factor: 4.406
Authors: Susmita Kashikar-Zuck; Susan T Tran; Kimberly Barnett; Maggie H Bromberg; Daniel Strotman; Soumitri Sil; Staci M Thomas; Naomi Joffe; Tracy V Ting; Sara E Williams; Gregory D Myer Journal: Clin J Pain Date: 2016-01 Impact factor: 3.442
Authors: Marina R Connolly; Jenna Y Chaudari; Ximeng Yang; Nam Ward; Rachel A Kitt; Rachel S Herrmann; Elliot J Krane; Alyssa A LeBel; Shannon M Smith; Gary A Walco; Steven J Weisman; Dennis C Turk; Robert H Dworkin; Jennifer S Gewandter Journal: J Pain Date: 2018-09-13 Impact factor: 5.820
Authors: Susmita Kashikar-Zuck; Natoshia Cunningham; Soumitri Sil; Maggie H Bromberg; Anne M Lynch-Jordan; Daniel Strotman; James Peugh; Jennie Noll; Tracy V Ting; Scott W Powers; Daniel J Lovell; Lesley M Arnold Journal: Pediatrics Date: 2014-02-24 Impact factor: 7.124